BIS-RNAI

pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection